RSV Vaccines for the World

18-20 November 2015, The Salk Institute, La Jolla, California, USA

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection, 2) immature immune system and maternal antibodies of newborn infants who are the primary subject population, and 3) imbalanced Th2-biased immune responses to a past vaccine candidate led to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. Currently a wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vector-based candidates. Though licensed vaccines remain to be developed, concerted efforts will lead researchers to reach the goal of attaining safe and effective RSV vaccines in the near future.

This second conference, following the RSVVW 2013 meeting held in Porto in 2013, will again aim to bring together RSV researchers and other interested parties and researchers to hear updates on progress towards the successful implementation of vaccines/vaccine strategies against the RSV pathogen. RSVVW 2015 will be of interest to researchers/contributors from academic programmes, industrial, governmental and regulatory groups.

The RSVVW 2015 meeting will comprise keynote presentations and special sessions and in addition the RSVVW 2015 organisers invite oral and poster abstract submissions to be considered for inclusion in the meeting schedule.

Scientific Advisory Panel

Gregory Glenn (Novavax, Gaithersburg, Maryland, USA)
Deborah Higgins (PATH, Seattle, Washington, USA)
Pedro Piedra (Baylor College of Medicine, Houston, Texas, USA)
Gale Smith (Novavax, Gaithersburg, Maryland, USA)
Louis Bont (University Medical Center Utrecht, Utrecht, The Netherlands)
Geeta Swamy (Duke College of Medicine, Durham, North Carolina, USA)
Edward Belongia (Center for Clinical Epidemiology and Population Health, Marshfield Clinic, Marshfield, Wisconsin, USA)
Larry Anderson (Emory University – Children’s Center, Atlanta, Georgia, USA)
Harish Nair (Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK)
Steven Varga (University of Iowa, Iowa City, Iowa, USA)
Rob Lambkin-Williams (hVIVO Ltd, London, UK)

Conference Scope

The RSVVW 2015 meeting is aimed at attracting a broader audience of RSV researchers and also vaccinologists/groups not necessarily directly involved with RSV research. The main topics/sessions will include:

  • Lessons learned from previous vaccine developments
  • Requirements induction of protective, safe and durable immune responses
  • Populations needing a vaccine and strategies for delivery
  • Infant Immunization – Maternal Immunization – Elderly Immunization
  • Current vaccines development
  • Clinical development of RSV vaccines: hurdles, opportunities and dead ends
  • Animal and challenge models
  • Antigens, adjuvants and vaccine approaches
  • RSV vaccines in the developing world
 

RSVVW 2015 Delegates

Login details will be supplied after you have registered for the event.

RSVVW 2015 Venue


RSVVW 2015 Sponsors

  • hVIVO
  • DNAvaccine.com
  • Aldevron
  • Inovio
  • Aragen
  • NatureGeneTherapy
  • Novavax
  • Mymetics

RSVVW 2015 Downloads

RSVVW 2015 Leaflet

RSVVW 2015 Mailing List

Name
E-mail Address
What is 3+2-1?